FDA Study is Designed to Justify a New BadAd Program for Consumers, IMHO

The FDA plans to do two new studies supposedly to gauge the “ability of consumers and healthcare professionals (HCPs) to independently identify deceptive prescription drug promotion” (see the Federal Register Noticehere).A closer examination of the proposal, however, suggests that the real goal is to promote the Agency's BadAd program and open it up to consumers.TheBad Ad Program is administered by the agency ’s Office of Prescription Drug Promotion (OPDP) in the Center for Drug Evaluation and Research. The program's goal is to help raise awareness among healthcare providers about misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.There have been several cases where the FDA sent out warning letters based on notices it received from the BadAd program (read, for example, “OMG. Kim Kardashian Shills for Pharma! No Worry - No Side Effects!”).According to aSTATnews article, “Awareness [of the BadAd program] is low, however, according to a study published in 2015 in the Journal of Health Care Communications, which surveyed doctors, nurses and physician assistants who provide ambulatory care.“The notice for the newest studies suggested the agency may consider creating such a program to prompt consumers to also report deceptive ads.”I was quoted in the article, saying “It’s possible the Bad Ad program doesn’t go far enough and the FDA is looking to crowd source in order to use the power of cons...
Source: Pharma Marketing Blog - Category: Pharmaceuticals Tags: FDA Study Source Type: blogs